Corneal Crosslinking for Treatment of Corneal Neovascularization
Price Vision Group · with Cornea Research Foundation of America · NCT04787471
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2, Phase 3
- Target enrollment
- 138
- US sites recruiting
- 1
- Study start
- May 3, 2021
- Record last updated
- September 17, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.
Being studied: 30 minute photoactivation of riboflavin 0.1%; 10 minute photoactivation of riboflavin 0.1%
Conditions: Corneal Neovascularization
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 18 years of age or older
- With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
- Signed written informed consent.
Exclusion Criteria
- Known sensitivity to treatment medications
- Current condition that in the investigator's opinion could compromise safety or data integrity.
- Pregnancy (including plan to become pregnant) or lactation during the course of the study
Recruiting US locations
Price Vision Group
Indianapolis, IN 46260
Site contact: Marianne Price, PhD · 317-814-2990 · mprice@cornea.org
Study contacts (from the official record)
- Marianne Price, PhD · 317-814-2990 · mprice@cornea.org